🚀 Accelerate your career with insights from leading scientists in #Alzheimers and related dementias at Alzheimer’s Fast Track, Nov. 12-14 in San Diego. ⌛ Act fast to reserve your spot for this one-of-a-kind immersive learning experience!. 🔗 Register at

Join Christian Howell, CEO of @cognitotx for an update on the HOPE Study, an innovative therapy that aims to activate gamma brain waves with the potential to protect memory, cognition, and daily function. We’ll explore what the science shows so far, what comes next, and take

📢 #BreakingNews in the fight against Alzheimer’s: The FDA has approved an at-home version of Leqembi (lecanemab-irmb), the first anti-amyloid therapy individuals can self-administer with a weekly injection that takes 15 seconds on average. This new option makes treatment more

A next-generation blood test may do more than diagnose Alzheimer’s—it could help doctors personalize treatment by revealing how far the disease has progressed. BrightFocus Alzheimer's Disease Research grant recipient, Dr. Gemma Salvadó, helped validate this promising new blood

RT @CornellNews: Researchers at @CornellBME have identified the signaling mechanism that triggers steroid-induced glaucoma by creating a 3D….

Join us live TODAY at 1 p.m. ET for a conversation with BrightFocus Foundation Scientific Affairs teammates Dr. Diane Bovenkamp and Dr. Sharyn Rossi as they discuss this year's Macular Degeneration Research bold and innovative projects. It’s your chance to learn how we identify

Researchers analyzing data from more than 600,000 older adults found that people who lived in areas with high lead pollution during the 1960s and early 1970s show a 20% higher likelihood of experiencing memory problems today. The results add to growing evidence that

Dr. Brittany Carr is using gene editing technology to understand why toxic debris builds up in our retinas as we age—a key cause of age-related macular degeneration (AMD). Her cutting-edge research, funded by BrightFocus Foundation's Macular Degeneration Research program, could

Could a diabetes drug help treat Alzheimer’s? 🧠💊 . Medicines like Ozempic and Wegovy are showing early promise for protecting brain cells and slowing memory loss. Large trials are underway now.

BrightFocus Alzheimer’s Disease Research-funded scientists are developing a home-based brain stimulation treatment that targets memory and mood—all without medication. Learn how this bold new approach could improve quality of life for people living with Alzheimer’s and their

Light therapy is emerging as a promising treatment for age-related macular degeneration. Listen to our full conversation with Dr. Richard B. Rosen from @MountSinaiNYC about the science behind photobiomodulation and the newly approved Valeda therapy:

RT @PeerView: Are you making discussions about #BrainHealth part of routine pt care? Get strategies for helping reduce risk for cognitive i….

🧠 Could the same drugs helping people lose weight and manage diabetes also guard against Alzheimer's? . New research suggests GLP-1 medications could protect brain health, improve memory, and slow neurodegeneration. Join Professor Paul Edison from Imperial College London as he

Join us today for an expert discussion with Dr. Amy Zhang from the University of Michigan Kellogg Eye Center as she explores advances in glaucoma management. Dr. Zhang will discuss innovative minimally invasive surgical techniques, at-home pressure monitoring technologies,.

Two innovative tests launched by C2N Diagnostics--and backed by early funding by BrightFocus Foundation's Alzheimer's Disease Research program--offer hope for more precise, accessible screening. The first test measures a novel tau protein marker that's closely linked to

People with Down syndrome face a high risk of Alzheimer’s. Alzheimer’s Disease Research-funded scientist Dr. Granholm-Bentley is leading a first-of-its-kind international brain bank to understand why—and find new ways to detect, prevent, and treat dementia for everyone. Learn

Mengya Zhao, PhD, a BrightFocus National Glaucoma Research grant recipient, uses innovative models to study neuronal resilience to glaucoma. Her findings could reveal survival signals in resistant retinal ganglion cells and guide therapies to protect more sensitive ones. Read

The U.S. POINTER study—the first large U.S. randomized controlled trial of its kind—found that both structured and self‑guided lifestyle interventions improved cognitive function in older adults at elevated dementia risk. The structured intervention delivered significantly

BrightFocus-funded scientist Dr. Sandeep Moothedath Subrahmanian of Penn State College of Medicine is studying how a “molecular switch” causes a stress response protein, REDD1, to build up and damage retinal cells in early macular degeneration. His goal: to stop the disease

From lifestyle changes that protect memory and cutting-edge blood tests to evidence that past lead exposure can impact brain health decades later, major findings at #AAIC2025 are shaping the future of Alzheimer's prevention, diagnosis, and care. Learn more:

🚨 Don't wait for symptoms to protect your sight. Join Dr. Amy Zhang from @UMKelloggEye on Wednesday, Aug 13 at 1pm ET to discover why proactive glaucoma care matters. We'll discuss how how cutting-edge options like minimally invasive surgery, at-home pressure monitoring, and